- Open
- 0.93
- High
- 1.00
- Low
- 0.90
- Close
- 0.95
- Change
- -0.03 (-2.70%)
- Volume
- 8,135,269
⌘K
| 21 Apr 2026 | 07:00:07 | NHS England commercial strategy for MT-RNR1 |
| 20 Apr 2026 | 07:00:08 | Interactive Investor Hub Updates |
| 16 Apr 2026 | 07:00:07 | CYP2C19 kit implemented in North Bristol NHS Trust |
| 30 Mar 2026 | 07:00:10 | Interim Results to 31 December 2025 |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 21 Apr 2026 | 07:00:07 | NHS England commercial strategy for MT-RNR1 |
| 20 Apr 2026 | 07:00:08 | Interactive Investor Hub Updates |
| 16 Apr 2026 | 07:00:07 | CYP2C19 kit implemented in North Bristol NHS Trust |
| 30 Mar 2026 | 07:00:10 | Interim Results to 31 December 2025 |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 12 Mar 2026 | 09:52:57 | Holding(s) in Company |
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |
| 12 Mar 2026 | 09:52:57 | Holding(s) in Company |
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |